ALISO VIEJO, Calif., Feb. 14, 2017 -- NVISION Eye Centers—a national leader in providing the finest suite of ophthalmology services for patients including: custom and Topographic LASIK, KAMRA Inlay, cataract surgery and other vision correction procedures—is pleased to announce today the appointment of Sanjeev Ganatra to Vice President of Corporate Development.
“We could not be more pleased to have Sanjeev joining as a senior leader in our organization,” said Tom Tooma, founder of NVISION. “Our team will benefit tremendously from his keen market insights and from his strategic approach to business development. I look forward to Sanjeev leading the pursuit of collaborative partnerships and accelerating our growth.”
Prior to joining NVISION, Sanjeev served on the executive team of VisionCare, Inc., a privately held ophthalmic medical device company, where he focused his efforts on corporate business development and healthcare marketing of the first in class CentraSight™ platform.
Prior to VisionCare, Sanjeev served ophthalmology in multiple commercial roles with ISTA Pharmaceuticals ranging from sales, analytics and marketing management, ultimately launching the BEPREVE® brand and responsible for the $700 million allergy franchise. At the time of ISTA’s acquisition by Bausch & Lomb, ISTA had grown to become the third largest branded prescription eye care business in the US.
“I’m excited to be a part of the NVISION team working to build and expand our network of corporate and provider partners to improve access to vision for all,” says Sanjeev Ganatra. “By being in more communities and broadening our service offerings, our patients can continue to enjoy the great NVISION experience for more of their eye care needs. I look forward to working with the team to further the successes that NVISION and its partners have enjoyed.”
Sanjeev received his MBA from the University of Southern California, and also holds a Bachelor’s degree in molecular biology from the University of California, San Diego.
ABOUT NVISION EYE CENTERS: NVISION Eye Centers is the premier provider of LASIK and cataract surgery in the US, with centers in California, Nevada, Oregon, Arizona and Toronto, Canada. An innovative leader in ophthalmology, NVISION is dedicated to providing the best patient experience through the use of the latest technology and treatment by the most talented and experienced surgeons in the industry. NVISION was founded in 2010 by Tom Tooma, M.D., one of the earliest pioneers of LASIK, who has performed more than 100,000 procedures throughout his esteemed career. With more than 1,900 eye doctors referring their patients and trusting their own eyes to NVISION surgeons, NVISION Eye Centers is the Eye Doctors' #1 Choice®. For more information, visit www.NVISIONCenters.com or call (877) 455-9942.


BP Nears $10 Billion Castrol Stake Sale to Stonepeak
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal
Nvidia and Groq Strike Strategic AI Inference Licensing Deal
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 



